Sign In
Buy NVS
$148.93
+1.85 (+1.26%)
At Close: Jun 22, 2026
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
01:15am, Monday, 23'rd Feb 2026
Basel, February 23, 2026 – Novartis will present data from five key abstracts evaluating the highly selective oral Bruton's tyrosine kinase inhibitor (BTKi) Rhapsido® (remibrutinib) in chronic spon
Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decades
02:47pm, Sunday, 22'nd Feb 2026
Novartis is a large drugmaker with a wide-ranging portfolio. Like all drugmakers, it faces the challenge of patent expirations.
Trump Says Tariffs Drove Novartis' $23 Billion US Expansion
05:05pm, Friday, 20'th Feb 2026
Novartis (NVS) is once again intersecting with US trade policy after President Donald Trump said his tariff strategy may have influenced the Swiss drugmaker's d
Novartis to Sell 70.68% Stake in India Unit for 14.46 Billion Rupees
10:01am, Friday, 20'th Feb 2026
Novartis (NVS) has agreed to divest its 70.68% stake in Novartis India Ltd. to a consortium of WaveRise Investments, ChrysCapital Fund X and Two Infinity Partne
Novartis To Sell India Stake For $159 Million
09:28am, Friday, 20'th Feb 2026
Novartis (NVS) is taking another step in its ongoing reshuffle, agreeing to sell its entire 70.68% stake in Novartis India for roughly $159 million to a private
China Universal Asset Management Co. Ltd. Grows Stake in Novartis AG $NVS
06:38am, Friday, 20'th Feb 2026
China Universal Asset Management Co. Ltd. increased its position in Novartis AG (NYSE: NVS) by 33.3% in the third quarter, according to the company in its most recent filing with the Securities and Ex
Trump meets Novartis CEO, says drugmaker building 11 US plants
10:38pm, Thursday, 19'th Feb 2026
U.S. President Donald Trump said he met Vas Narasimhan, the chief executive officer of Swiss drugmaker Novartis , at the White House on Wednesday.
Novartis to sell entire 71% stake in Indian unit to consortium of WaveRise Investments
10:27pm, Thursday, 19'th Feb 2026
Swiss pharmaceutical firm Novartis said on Friday that it would sell its entire 70.68% stake in its listed Indian unit to a consortium of WaveRise Investments, ChrysCapital and Two Infinity Partners.
HighTower Advisors LLC Buys 10,543 Shares of Novartis AG $NVS
04:20am, Thursday, 19'th Feb 2026
HighTower Advisors LLC increased its stake in shares of Novartis AG (NYSE: NVS) by 4.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchan
Unnatural Products, Novartis sign license deal worth up to $1.7 billion for cardiovascular program
08:10am, Wednesday, 18'th Feb 2026
Unnatural Products said on Wednesday it has signed a licensing agreement with Novartis to develop macrocyclic peptide-based therapies for a cardiovascular program.
Unnatural Products Announces Licensing Agreement with Novartis to Develop Macrocyclic Peptide Therapeutics
08:00am, Wednesday, 18'th Feb 2026
SANTA CRUZ, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, today announ
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
01:15am, Wednesday, 18'th Feb 2026
Basel, February 18, 2026 – Novartis today announced positive topline results from its pivotal Phase III RemIND trial of oral remibrutinib in chronic inducible urticaria (CIndU)1. The primary endpoin
Ameritas Advisory Services LLC Cuts Stake in Novartis AG $NVS
03:30am, Monday, 16'th Feb 2026
Ameritas Advisory Services LLC cut its stake in Novartis AG (NYSE: NVS) by 61.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The inst
Atria Investments Inc Has $7.50 Million Position in Novartis AG $NVS
04:02am, Saturday, 14'th Feb 2026
Atria Investments Inc boosted its stake in shares of Novartis AG (NYSE: NVS) by 9.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commi
Novartis AG $NVS Stake Raised by Assetmark Inc.
03:24am, Saturday, 14'th Feb 2026
Assetmark Inc. raised its stake in shares of Novartis AG (NYSE: NVS) by 12.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned
